HPV and RNA Binding Proteins: What We Know and What Remains to Be Discovered

被引:0
|
作者
Graham, Sheila V. [1 ]
机构
[1] Univ Glasgow, Sch Infect & Immun, Coll Med Vet & Life Sci, MRC Univ Glasgow Ctr Virus Res, Glasgow G61 1QH, Scotland
来源
VIRUSES-BASEL | 2024年 / 16卷 / 05期
关键词
Papillomaviruses; RNA binding proteins; RNA processing; epithelial differentiation; life cycle; HUMAN-PAPILLOMAVIRUS TYPE-16; NEGATIVE REGULATORY ELEMENT; LATE GENE-EXPRESSION; CELLULAR SPLICING FACTOR; DNA-DAMAGE RESPONSE; MESSENGER-RNA; L1; PROTEIN; U1; SNRNP; IN-VITRO; POLYADENYLATION ELEMENT;
D O I
10.3390/v16050783
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Papillomavirus gene regulation is largely post-transcriptional due to overlapping open reading frames and the use of alternative polyadenylation and alternative splicing to produce the full suite of viral mRNAs. These processes are controlled by a wide range of cellular RNA binding proteins (RPBs), including constitutive splicing factors and cleavage and polyadenylation machinery, but also factors that regulate these processes, for example, SR and hnRNP proteins. Like cellular RNAs, papillomavirus RNAs have been shown to bind many such proteins. The life cycle of papillomaviruses is intimately linked to differentiation of the epithelial tissues the virus infects. For example, viral late mRNAs and proteins are expressed only in the most differentiated epithelial layers to avoid recognition by the host immune response. Papillomavirus genome replication is linked to the DNA damage response and viral chromatin conformation, processes which also link to RNA processing. Challenges with respect to elucidating how RBPs regulate the viral life cycle include consideration of the orchestrated spatial aspect of viral gene expression in an infected epithelium and the epigenetic nature of the viral episomal genome. This review discusses RBPs that control viral gene expression, and how the connectivity of various nuclear processes might contribute to viral mRNA production.
引用
收藏
页数:17
相关论文
共 50 条
  • [41] Lp(a): What we know, what we don't know and what we hope for
    Amengual, A. Moya
    Serrano-Cumplido, A.
    MEDICINA DE FAMILIA-SEMERGEN, 2025, 51 (07):
  • [42] What We Notice, What We Know
    Gundy, Jeff
    GEORGIA REVIEW, 2009, 63 (01): : 144 - 152
  • [43] Bridge to Recovery: What Remains to be Discovered?
    Ibrahim, Michael
    Terracciano, Cesare M.
    Yacoub, Magdi H.
    CARDIOLOGY CLINICS, 2011, 29 (04) : 531 - +
  • [44] What we think and what we know
    Buse, J
    Raftery, L
    DIABETES CARE, 2002, 25 (10) : 1876 - 1878
  • [45] WHAT WE KNOW AND WHAT WE DONT
    HILLMAN, BJ
    INVESTIGATIVE RADIOLOGY, 1991, 26 (05) : 401 - 401
  • [46] What We Know Is Not What We Feel
    Suk, Julie
    GEORGIA REVIEW, 2008, 62 (04): : 747 - 748
  • [47] Pathology of catheter-related complications: what we need to know and what should be discovered
    Wang, Lihua
    Jia, Lan
    Jiang, Aili
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2022, 50 (10)
  • [48] ALLIANCES IN HEALTH-CARE - WHAT WE KNOW, WHAT WE THINK WE KNOW, AND WHAT WE SHOULD KNOW
    ZUCKERMAN, HS
    KALUZNY, AD
    RICKETTS, TC
    HEALTH CARE MANAGEMENT REVIEW, 1995, 20 (01) : 54 - 64
  • [49] We know what we are, but not what we may be
    Schauffer, Dennis
    TD-THE JOURNAL FOR TRANSDISCIPLINARY RESEARCH IN SOUTHERN AFRICA, 2006, 2 (02) : 379 - 390
  • [50] The eosinophilia-myalgia syndrome: What we know, what we think we know and what we need to know
    Clauw, DJ
    Pincus, T
    JOURNAL OF RHEUMATOLOGY, 1996, 23 : 2 - 6